![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Backs UCB’s, Cizma’s Psoriatic Arthritis Drugs
NICE Backs UCB’s, Cizma’s Psoriatic Arthritis Drugs
January 13, 2017
The UK’s National Institute for Health and Care Excellence is backing the coverage of UCB’s Cimzia and Novartis’ Cosentyx to use either alone or in combination with methotrexate to treat psoriatic arthritis.
Both drugs can be used with methotrexate, if the person has had a TNF-alpha inhibitor but the disease has stopped responding to the drug after the first 12 weeks and if the drug is provided under the controlled conditions.
Upcoming Events
-
21Oct